Researchers at Anadolu University and Bilecik Seyh Edebali University have described quinazolinone derivative compounds acting as EGFR (HER1; erbB1) inhibitors and apoptosis inducers reported to be useful for the treatment of lung cancer.
Signet Therapeutics Co. Ltd. has divulged α, β-unsaturated amide compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Scientists at Livzon Pharmaceutical Group Inc., Shanghai Institute of Organic Chemistry and the University of Michigan have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bound to a cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) targeting moiety through a linker reported to be useful for the treatment of cancer.
Researchers from Imperial College London presented data from a study that aimed to assess the role of miR-1271-5p in prostate cancer (PCa) progression.
Rakovina Therapeutics Inc. and Variational AI Inc. have entered into a research collaboration to identify and develop novel small-molecule therapies against DNA damage response (DDR) targets for the treatment of cancer.
Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer. CID-078 was developed as a macrocycle that binds to the hydrophobic patch of cyclins A and B and blocks RxL-dependent interactions of proteins, such as that of E2F1 with cyclin A-CDK2 and Myt1 with cyclin B-CDK1.
Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5)/methylosome protein 50 (MEP50) interaction inhibitors reported to be useful for the treatment of cancer.
RSS
